用低剂量thalidomide和colchicine治疗难治口腔的成功缓解:一个病例报告
Shun-Yu Kan1, Yu-Kai Sung2, Chia-Lu Hsu3
1School of Dentistry, National Defense Medical University, Number 161, Section 6, Minquan East Road, Neihu District, Taipei City 114, Taiwan.
Reports (MDPI)
|February 20, 2026
概括
抵抗标准治疗的不耐药口腔可能受益于低剂量thalidomide和colchicine的联合治疗. 这种方法使得一个没有对常规口腔治疗反应的患者持续缓解.
科学领域:
- 牙科 牙科是指牙科的专业.
- 口腔医学是指口腔医学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 口腔是常见的,标准治疗包括取消病因和药物治疗,通常是局部皮质类固醇.
- 耐火性口腔严重影响患者的生活质量,需要系统性评估.
- 传统的治疗方法,包括皮质固醇和病因因子去除,在这种情况下是无效的.
研究的目的:
- 呈现一种耐火性口腔病例,该病例对多种常规治疗具有抗性.
- 探索替代治疗策略,以挑战口腔病例.
主要方法:
- 一名患有耐火性口腔的患者接受了牙科干预 (牙圆形化,闭合性咬伤板) 以解决与帕金森病相关的创伤来源.
- 进行了病变的活检.
- 治疗包括常规疗法 (皮质类固醇) 和病因因子去除,所有这些都是无效的.
主要成果:
- 开始使用低剂量thalidomide (50 mg/天) 和colchicine (1.5 mg/天) 的联合治疗.
- 患者实现了显著的临床改善和完全缓解.
- 缓解持续了六个多月,没有复发.
结论:
- 低剂量thalidomide和colchicine的联合治疗显示出对不耐药口腔的治疗有希望,这种口腔对传统治疗无反应.
- 这种治疗方法需要在更大的研究中进一步调查疗效和安全性.
- 这些发现产生了假设,表明了对困难的口腔病例的潜在新治疗途径.
相关概念视频
01:29Drugs for Treatment of Ulcerative Colitis in IBD
553
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
553
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
547
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
547
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
583
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
583
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
1.7K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
1.7K
01:26Peptic Ulcer Disease IV: Management
553
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
553
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
1.5K
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
1.5K